VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

FibroGen, Inc. (FGEN)

Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value

Popular:

Full Profile →

MODEL VERDICT

industrialBiotechnologyImmunology and Inflammation Therapies

MODEL VERDICT

N/A

Blended Fair ValueN/A

Expected UpsideN/A

Coverage0 / 10 prioritized multiples
Peer Universe10 industrial names
Scenario AnalysisMonte Carlo · 10,000 paths

Confidence

59 / 100

Data coverage, stability, peer fit

Monte Carlo P₅₀

N/A

P₅–P₉₅: N/A · N/A

Conviction

N/A

—

Industry P/E

19.0×

FGEN: -15.6× · 182% discount to median

PEG Ratio

N/A

—

Historical Percentile

—th

—

MODEL SUMMARY

Fair value — model is monitoring conditions.

This is a quantitative model output, not a recommendation. See full disclaimer below.

Model Signal Strength

Composite score derived from valuation, quality, and risk factors

SIGNALNEUTRAL

Above 0.75: High Conviction0.55–0.75: Monitor / Under ReviewBelow 0.55: Below Threshold

Signal Components (Weighted)

Model Confidence

59 → 0.59

P50 Price Spread

+0% → +0.00

Margin Risk Penalty

Z+0.0 → 0.00

Margin of Safety

+0.0% → 0.00

Weighted Calculation

0.18 = (0.59 × 30%) + (0.00 × 15%) + (0.00 × 15%) + (0.00 × 40%)

Weights: MOS (40%), Confidence (30%), Margin Risk (15%), P50 Spread (15%)

Model Analysis Zone

Quantitative model thresholds · For educational and research purposes only

BELOW THRESHOLD

Model-Derived Price Zones

Model Threshold Conditions

Model thresholds are satisfied when all 4 conditions align:

CONDITIONS: 0 of 4 MET

Monitor price and margins

Portfolio Fit Analysis

Hypothetical scenario analysis

Portfolio Archetype

Opportunistic

Situation-dependent thesis. Evaluate on case-by-case basis.

CORRELATION TO S&P 500

0.23

LOW

Good diversification

POSITION SIZING CONTEXT

1–3%typical range for this archetype

Not a recommendation — sizing depends on individual portfolio, risk tolerance, and concentration

THRESHOLD PROXIMITY

1 / 5 — Low

Model does not indicate urgency. Monitor for price and margin developments.

Hypothetical Scenario

Illustrative scenario: A hypothetical tiered approach spread over 18–36 months. Position sizing should reflect individual risk tolerance, existing portfolio concentration, and correlation with current holdings. This is not a recommendation.

Quality Drivers

Justified premium -40%

Growth-2.00

Revenue CAGRAt/Below Peers

EPS CAGRModerate

Profitability+2.00

ROICSuperior

Net MarginAbove Industry

Balance Sheet+0.00

Net Debt / EBITDAAdequate

Interest CoverageAcceptable

Composite Premium-40.0%

Growth 50% · Profitability 35% · Leverage 15%

Total Adjustment: ×0.600

*Quality adjustments cap at ±40% to prevent runaway premiums. Inputs sourced from trailing twelve months and five-year CAGR averages.

Regression-Based Fair Multiples

Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.

P/E Ratio

Expected1.00

Current-15.62

Premium-1662.5%

Cheap

EV/EBITDA

Expected1.00

Current—

Premium—

Fair

Historical Multiple Statistics

Based on 7 years of annual data

Multiple	Avg	Median	Min	Max	Std
P/TBV	172.09	178.77	142.08	188.74	20.99
P/B Ratio	172.09	178.77	142.08	188.74	20.99
P/S Ratio	255.25	266.32	44.72	472.54	183.06

Next Actions

Explore related analysis

Full Stock Profile Valuation Overview DCF Valuation Estimates & Forecasts Total Return Calculator Stock Screener

Frequently Asked Questions

ValuationIs FGEN undervalued based on peer comparison?

Insufficient data to determine relative valuation for FGEN.

ValuationWhat is FGEN's fair value from multiples?

Fair value could not be computed for FGEN due to insufficient comparable data.

ValuationHow does FGEN's P/E compare to the industry?

FGEN's current P/E of -15.6x compares to the industry median of 19.0x (4 peers in the group). This represents a -182.3% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.

ValuationWhat do analysts think about FGEN?

14 analysts cover FGEN with a consensus rating of Hold. The consensus price target is $28.00 (range: $28.00 — $28.00), implying +273.3% upside from the current price. Grade breakdown: Strong Buy (0), Buy (5), Hold (7), Sell (2), Strong Sell (0).

MethodologyHow confident is the relative valuation for FGEN?

The model confidence score is 59/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.

RiskWhat are the biggest risks to FGEN's valuation?

The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.

RiskWhat does "peak earnings risk" mean for FGEN?

Peak earnings risk data is not available for FGEN.

LegalDoes this dashboard provide investment advice?

No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.

All Research Documents

Institutional-grade research documentation

Relative Valuation

Peer universe construction, Monte Carlo simulation, confidence scoring, and signal frameworks.

→

Estimates & Forecasts

Revenue CAGR blending, margin path engine, analyst fusion, and scenario analysis.

→

DCF Intrinsic Value

Two-stage discounted cash flow with WACC, Gordon Growth terminal value, and sensitivity analysis.

→

MODEL VERDICT

industrialBiotechnologyImmunology and Inflammation Therapies

MODEL VERDICT

N/A

Blended Fair ValueN/A

Expected UpsideN/A

Coverage0 / 10 prioritized multiples
Peer Universe10 industrial names
Scenario AnalysisMonte Carlo · 10,000 paths

Confidence

59 / 100

Data coverage, stability, peer fit

Monte Carlo P₅₀

N/A

P₅–P₉₅: N/A · N/A

Conviction

N/A

—

Industry P/E

19.0×

FGEN: -15.6× · 182% discount to median

PEG Ratio

N/A

—

Historical Percentile

—th

—

MODEL SUMMARY

Fair value — model is monitoring conditions.

This is a quantitative model output, not a recommendation. See full disclaimer below.

Model Signal Strength

Composite score derived from valuation, quality, and risk factors

SIGNALNEUTRAL

Above 0.75: High Conviction0.55–0.75: Monitor / Under ReviewBelow 0.55: Below Threshold

Signal Components (Weighted)

Model Confidence

59 → 0.59

P50 Price Spread

+0% → +0.00

Margin Risk Penalty

Z+0.0 → 0.00

Margin of Safety

+0.0% → 0.00

Weighted Calculation

0.18 = (0.59 × 30%) + (0.00 × 15%) + (0.00 × 15%) + (0.00 × 40%)

Weights: MOS (40%), Confidence (30%), Margin Risk (15%), P50 Spread (15%)

Model Analysis Zone

Quantitative model thresholds · For educational and research purposes only

BELOW THRESHOLD

Model-Derived Price Zones

Model Threshold Conditions

Model thresholds are satisfied when all 4 conditions align:

CONDITIONS: 0 of 4 MET

Monitor price and margins

Portfolio Fit Analysis

Hypothetical scenario analysis

Portfolio Archetype

Opportunistic

Situation-dependent thesis. Evaluate on case-by-case basis.

CORRELATION TO S&P 500

0.23

LOW

Good diversification

POSITION SIZING CONTEXT

1–3%typical range for this archetype

Not a recommendation — sizing depends on individual portfolio, risk tolerance, and concentration

THRESHOLD PROXIMITY

1 / 5 — Low

Model does not indicate urgency. Monitor for price and margin developments.

Hypothetical Scenario

Illustrative scenario: A hypothetical tiered approach spread over 18–36 months. Position sizing should reflect individual risk tolerance, existing portfolio concentration, and correlation with current holdings. This is not a recommendation.

Quality Drivers

Justified premium -40%

Growth-2.00

Revenue CAGRAt/Below Peers

EPS CAGRModerate

Profitability+2.00

ROICSuperior

Net MarginAbove Industry

Balance Sheet+0.00

Net Debt / EBITDAAdequate

Interest CoverageAcceptable

Composite Premium-40.0%

Growth 50% · Profitability 35% · Leverage 15%

Total Adjustment: ×0.600

*Quality adjustments cap at ±40% to prevent runaway premiums. Inputs sourced from trailing twelve months and five-year CAGR averages.

Regression-Based Fair Multiples

Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.

P/E Ratio

Expected1.00

Current-15.62

Premium-1662.5%

Cheap

EV/EBITDA

Expected1.00

Current—

Premium—

Fair

Historical Multiple Statistics

Based on 7 years of annual data

Multiple	Avg	Median	Min	Max	Std
P/TBV	172.09	178.77	142.08	188.74	20.99
P/B Ratio	172.09	178.77	142.08	188.74	20.99
P/S Ratio	255.25	266.32	44.72	472.54	183.06

Next Actions

Explore related analysis

Full Stock Profile Valuation Overview DCF Valuation Estimates & Forecasts Total Return Calculator Stock Screener

Frequently Asked Questions

ValuationIs FGEN undervalued based on peer comparison?

Insufficient data to determine relative valuation for FGEN.

ValuationWhat is FGEN's fair value from multiples?

Fair value could not be computed for FGEN due to insufficient comparable data.

ValuationHow does FGEN's P/E compare to the industry?

FGEN's current P/E of -15.6x compares to the industry median of 19.0x (4 peers in the group). This represents a -182.3% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.

ValuationWhat do analysts think about FGEN?

14 analysts cover FGEN with a consensus rating of Hold. The consensus price target is $28.00 (range: $28.00 — $28.00), implying +273.3% upside from the current price. Grade breakdown: Strong Buy (0), Buy (5), Hold (7), Sell (2), Strong Sell (0).

MethodologyHow confident is the relative valuation for FGEN?

The model confidence score is 59/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.

RiskWhat are the biggest risks to FGEN's valuation?

The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.

RiskWhat does "peak earnings risk" mean for FGEN?

Peak earnings risk data is not available for FGEN.

LegalDoes this dashboard provide investment advice?

No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.